OCS: Oculis Holding AG

OCS新闻

• 06:30 Oculis To Report Topline Results Around Year-End 2026 From First Genotype-Guided Registrational Dry Eye Trial Of Licaminlimab, Now Fully Randomized With 176 Patients, Two-Thirds Carrying Target TNFR1 Variant
• 06:30 Oculis将于2026年底前后公布licaminlimab首个基因型指导注册性干眼试验的主要结果；该试验现已完成全部随机化，共176名患者，其中三分之二携带目标TNFR1变体
• 12:35 After Plunging 24% in 4 Weeks, Here's Why the Trend Might Reverse for Oculis Holding AG (OCS)
• 09:30 Strength Seen in Halozyme Therapeutics (HALO): Can Its 3.3% Jump Turn into More Strength?
• 12:31 Apple To Rally Around 13%? Here Are 10 Top Analyst Forecasts For Friday
• 12:31 苹果股价将上涨13%？以下是周五的10个顶级分析师预测
• 10:53 HC Wainwright & Co. Maintains Buy on Oculis Holding, Raises Price Target to $39
• 10:53 HC Wainwright & Co.维持对Oculis Holding的买入评级，将目标股价上调至39美元
• 20:28 Oculis Holding AG: Navigating Through Major Trial Setback (NASDAQ:OCS)
• 13:55 Wall Street Analysts Believe Oculis Holding AG (OCS) Could Rally 199.75%: Here's is How to Trade
• 13:55 Does Oculis Holding AG (OCS) Have the Potential to Rally 187.83% as Wall Street Analysts Expect?
• 02:35 Oculis Holding AG (OCS) Reports Q2 Loss, Tops Revenue Estimates
• 21:20 Vertex Pharmaceuticals (VRTX) Q2 Earnings Lag Estimates
• 14:16 Oculis Holding: Study Setback For Eye Drop Therapy Suggests Hold Rating (NASDAQ:OCS)